Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation.

John Dernellis1, Maria Panaretou

  • 1Department of Cardiology, Vostanion Hospital, 1 Kathigitou Karakatsani Street, 81100 Mytilini, Greece. dernellis@yahoo.gr

European Heart Journal
|July 3, 2004

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Relationship Between C-reactive Protein Concentrations During Glucocorticoid Therapy And Recurrent Atrial Fibrillation.

    • Low-dose methylprednisolone significantly reduced recurrent atrial fibrillation (AF) and permanent AF. C-Reactive Protein (CRP) levels are a key risk factor for AF recurrence.

    Area of Science:

    • Cardiology
    • Inflammation Research
    • Pharmacology

    Background:

    • Limited data exists on C-Reactive Protein (CRP) lowering effects on recurrent atrial fibrillation (AF).
    • CRP is a known inflammatory marker, but its direct impact on AF recurrence requires further investigation.

    Purpose of the Study:

    • To investigate the efficacy of low-dose glucocorticoid therapy in reducing recurrent and permanent atrial fibrillation (AF).
    • To determine if C-Reactive Protein (CRP) concentration is a predictor of AF recurrence.

    Main Methods:

    • A randomized controlled trial comparing low-dose methylprednisolone with placebo in 104 patients with persistent AF.
    • Methylprednisolone was administered for 4 weeks (16 mg) tapered to 4 mg for 4 months.
    • Recurrent AF and permanent AF were monitored as primary and expanded end-points, respectively. CRP levels were analyzed during follow-up.

    Main Results:

    • Methylprednisolone significantly reduced recurrent AF from 50% to 9.6% and permanent AF from 29% to 2% compared to placebo (P < 0.001).
    • Elevated average CRP concentrations during follow-up were significant predictors for both recurrent (RR=6.72, P=0.006) and permanent AF (RR=11.67, P=0.0006).

    Conclusions:

    • C-Reactive Protein (CRP) concentration is a significant risk factor for recurrent and permanent atrial fibrillation (AF).
    • Low-dose methylprednisolone therapy is effective in preventing recurrent and permanent AF.

    Related Experiment Videos